| A | B | C | D | E | F | G | H | I | J | |
|---|---|---|---|---|---|---|---|---|---|---|
1 | CLINICAL TRIALS | |||||||||
2 | PANCREATIC CANCER - Stage IV / Recurrent / Neuroendocrine Tumors | |||||||||
3 | Source: clinicaltrials.gov | |||||||||
4 | ||||||||||
5 | ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process. | Contact Information | ||||||||
6 | No. | Link | Title | Official Title | Purpose | Citation | Organization/Sponsor | Collaborator | Status | Classification |
7 | ||||||||||
8 | 1 | http://clinicaltrials.gov/ct2/show/NCT01272791 | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer | A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer | The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab. | http://clinicaltrials.gov/ct2/show/NCT01272791 - Retrieved October 2011 | Peregrine Pharmaceuticals | Currently recruiting | Stage IV | |
9 | 2 | http://clinicaltrials.gov/ct2/show/NCT01098344 | MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery | A Cancer Research UK Phase I/IIa Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage IV Pancreatic Cancer | This phase I/II trial is studying the side effects and best dose of giving MK0752 together with gemcitabine hydrochloride and to see how well it works in treating patients with stage IV pancreatic cancer that cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT01098344 - Retrieved October 2011 | Cancer Research UK | Currently recruiting | Stage IV | |
10 | 3 | http://clinicaltrials.gov/ct2/show/NCT01191684 | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer | A Phase I Study of an MVA Vaccine Targeting P53 in Cancer | This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01191684 - Retrieved October 2011 | City of Hope Medical Center | National Cancer Institute | Not yet recruiting | Stage IV |
11 | 4 | http://clinicaltrials.gov/ct2/show/NCT01227018 | Hsp90 Inhibitor STA-9090 as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | Phase II Study of STA-9090 as Second-Line Therapy for Metastatic Pancreas Cancer | This phase II trial is studying how well hsp90 inhibitor STA-9090 as second-line therapy works in treating patients with metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01227018 - Retrieved October 2011 | Vanderbilt-Ingram Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
12 | 5 | http://clinicaltrials.gov/ct2/show/NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors | This phase I clinical trial is studying the side effects and best dose of treated T cells when given together with cyclophosphamide, fludarabine phosphate, and aldesleukin in treating patients with cancer. | http://clinicaltrials.gov/ct2/show/NCT01212887 - Retrieved October 2011 | Cancer Research UK | Currently recruiting | Stage IV | |
13 | 6 | http://clinicaltrials.gov/ct2/show/NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors | This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01131234 - Retrieved October 2011 | Princess Margaret Hospital, Canada | National Cancer Institute | Currently recruiting | Stage IV |
14 | 7 | http://clinicaltrials.gov/ct2/show/NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer | Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer | This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell lung cancer. | http://clinicaltrials.gov/ct2/show/NCT01282333 - Retrieved October 2011 | University of Pittsburgh | National Cancer Institute | Currently recruiting | Stage IV |
15 | 8 | http://clinicaltrials.gov/ct2/show/NCT01064622 | Gemcitabine Hydrochloride With or Without GDC-0449 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747) | This randomized phase II trial is studying gemcitabine hydrochloride and GDC-0449 to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01064622 - Retrieved October 2011 | University of Chicago | National Cancer Institute | Currently recruiting | Stage IV |
16 | 9 | http://clinicaltrials.gov/ct2/show/NCT01233375 | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression | The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT01233375 - Retrieved October 2011 | Clovis Oncology, Inc. | Currently recruiting | Stage IV | |
17 | 10 | http://clinicaltrials.gov/ct2/show/NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin®) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer | This phase III clinical trial is studying how well giving carboplatin and paclitaxel with or without viral therapy work in treating patients with recurrent or metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01280058 - Retrieved October 2011 | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute | National Cancer Institute | Currently recruiting | Stage IV |
18 | 11 | http://clinicaltrials.gov/ct2/show/NCT01229943 | Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors | This randomized phase II trial is studying how well giving everolimus and octreotide together with or without bevacizumab works in treating patients with locally advanced or metastatic pancreatic neuroendocrine tumors that cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT01229943 - Retrieved October 2011 | Cancer and Leukemia Group B | National Cancer Institute | Currently recruiting | Stage IV |
19 | 12 | http://clinicaltrials.gov/ct2/show/NCT00082862 | Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer | A Phase II Clinical Trial of a Timing/Schedule Optimized Combined-Modality Regimen: Cisplatin + Metronomic Low-Dose Interferon-α (IFN-α) Followed by Gemcitabine HCl (GEMZAR) in Combination With Mild, Fever-Range Whole-Body Hyperthermia (FR-WBH) in Patients With Advanced, Inoperable Pancreatic Cancer | This phase II trial is studying how well giving cisplatin, gemcitabine, and metronomic low-dose interferon alfa together with fever-range whole-body hyperthermia works in treating patients with inoperable or metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00082862 - Retrieved October 2011 | The University of Texas Health Science Center, Houston | Currently recruiting | Stage IV | |
20 | 13 | http://clinicaltrials.gov/ct2/show/NCT00669734 | Vaccine Therapy and GM-CSF in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | Immunotherapy for Unresectable Pancreas Cancer: A Phase I Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GMCSF) | This phase I trial is studying the side effects and best dose of vaccine therapy when given together with GM-CSF in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT00669734 - Retrieved October 2011 | University of Medicine and Dentistry New Jersey | National Cancer Institute | Currently recruiting | Stage IV |
21 | 14 | http://clinicaltrials.gov/ct2/show/NCT01167738 | Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer | A Randomized Phase II Study of Chemotherapy ± Metformin in Metastatic Pancreatic Cancer | This randomized phase II trial is studying giving cisplatin, epirubicin hydrochloride, capecitabine, and gemcitabine hydrochloride together with metformin hydrochloride to see how well it works compared to cisplatin, epirubicin hydrochloride, capecitabine, and gemcitabine hydrochloride alone in treating patients with metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01167738 - Retrieved October 2011 | Istituto Scientifico H. San Raffaele | Currently recruiting | Stage IV | |
22 | 15 | http://clinicaltrials.gov/ct2/show/NCT00967603 | Sunitinib Malate or Standard of Care and Observation in Treating Patients With Metastatic Pancreatic Cancer | Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer: a Phase II Randomized Trial. | This randomized phase II trial is studying sunitinib malate to see how well it works compared with standard of care and observation in treating patients with metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00967603 - Retrieved October 2011 | Istituto Scientifico H. San Raffaele | Currently recruiting | Stage IV | |
23 | 16 | http://clinicaltrials.gov/ct2/show/NCT00735917 | AZD0530 in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer | This phase II trial is studying how well AZD0530 works in treating patients with previously treated metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00735917 - Retrieved October 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting | Stage IV |
24 | 17 | http://clinicaltrials.gov/ct2/show/NCT01232829 | RO4929097 in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | This phase II trial is studying how well RO4929097 works in treating patients with previously treated metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01232829 - Retrieved October 2011 | University of Colorado, Denver | National Cancer Institute | Currently recruiting | Stage IV |
25 | 18 | http://clinicaltrials.gov/ct2/show/NCT00987766 | Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer | Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. | This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with gemcitabine hydrochloride and oxaliplatin in treating patients with advanced biliary tract cancer, pancreatic cancer, duodenal cancer, or ampullary cancer. | http://clinicaltrials.gov/ct2/show/NCT00987766 - Retrieved October 2011 | Vanderbilt-Ingram Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
26 | 19 | http://clinicaltrials.gov/ct2/show/NCT01222689 | AZD6244 and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Is Refractory to Gemcitabine Hydrochloride | A Phase 2 Study of AZD6244 Plus Erlotinib for Advanced Gemcitabine-Refractory Pancreatic Adenocarcinoma | This phase II trial is studying how well giving AZD6244 and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to gemcitabine hydrochloride | http://clinicaltrials.gov/ct2/show/NCT01222689 - Retrieved October 2011 | University of California, San Francisco | National Cancer Institute | Currently recruiting | Stage IV |
27 | 20 | http://clinicaltrials.gov/ct2/show/NCT00964171 | Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas. | This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00964171 - Retrieved October 2011 | Institut Bergonié | National Cancer Institute | Currently recruiting | Stage IV |
28 | 21 | http://clinicaltrials.gov/ct2/show/NCT01339754 | Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy | Salvage Therapy With Trabectedin in Metastatic Pancreatic Adenocarcinoma: A Single-Arm Phase II Trial | This phase II trial is studying how well trabectedin works in treating patients with metastatic pancreatic cancer after first-line chemotherapy. | http://clinicaltrials.gov/ct2/show/NCT01339754 - Retrieved October 2011 | Istituto Scientifico H. San Raffaele | Currently recruiting | Stage IV | |
29 | 22 | http://clinicaltrials.gov/ct2/show/NCT00662688 | Gemcitabine With or Without Capecitabine and/or Dalteparin in Treating Patients With Metastatic Pancreatic Cancer | Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas | This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine. | http://clinicaltrials.gov/ct2/show/NCT00662688 - - Retrieved October 2011 | Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) | Currently recruiting | Stage IV | |
30 | 23 | http://clinicaltrials.gov/ct2/show/NCT00867126 | Pioglitazone as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Treatment With Gemcitabine | A Pilot Study of Pioglitazone as Second Line Therapy for Patients With Previously Treated Metastatic Adenocarcinoma of the Pancreas With Disease Progression After Gemcitabine Based Chemotherapy | This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT00867126 - Retrieved October 2011 | Simmons Cancer Center | Currently recruiting | Stage IV | |
31 | 24 | http://clinicaltrials.gov/ct2/show/NCT00900003 | Studying Biomarkers in Patients With Pancreatic Cancer | Developing Biomarkers in Pancreatic Cancer | This research study is looking at biomarkers in patients with pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00900003 - Retrieved October 2011 | Vanderbilt-Ingram Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
32 | 25 | http://clinicaltrials.gov/ct2/show/NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease | This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders. | http://clinicaltrials.gov/ct2/show/NCT00830557 - Retrieved October 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting | Stage IV |
33 | 26 | http://clinicaltrials.gov/ct2/show/NCT01327794 | Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer | The Relationship of Serum 25-Hydroxyvitamin D to Overall Survival in Advanced Pancreatic Cancer | This research trial is studying the relationship between vitamin D biomarkers and survival in blood samples from patients with advanced pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01327794 - Retrieved October 2011 | Cancer and Leukemia Group B | National Cancer Institute | Currently recruiting | Stage IV |
34 | 27 | http://clinicaltrials.gov/ct2/show/NCT01145456 | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | A Phase I Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors | This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01145456 - Retrieved October 2011 | Princess Margaret Hospital, Canada | National Cancer Institute | Currently recruiting | Stage IV |
35 | 28 | http://clinicaltrials.gov/ct2/show/NCT01433263 | Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas | A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas | A safety & efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas | http://clinicaltrials.gov/ct2/show/NCT01433263 - Retrieved October 2011 | Novartis | Currently recruiting | Stage IV | |
36 | 29 | http://clinicaltrials.gov/ct2/show/NCT01196247 | A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer | Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer | The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival. | http://clinicaltrials.gov/ct2/show/NCT01196247 - Retrieved October 2011 | TGen Drug Development Services | Scottsdale Healthcare; Stand Up To Cancer; AACR | Currently recruiting | Stage IV |
37 | 30 | http://clinicaltrials.gov/ct2/show/NCT01437007 | TKM 080301 for Primary or Secondary Liver Cancer | A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01437007 - Retrieved October 2011 | National Cancer Institute | Currently recruiting | Stage IV | |
38 | 31 | http://clinicaltrials.gov/ct2/show/NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma | The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT01124786 - Retrieved October 2011 | Clovis Oncology, Inc. | Currently recruiting | Stage IV | |
39 | 32 | http://clinicaltrials.gov/ct2/show/NCT01243775 | BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC (BELOXAN) | Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer | Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC). The majority of patients with NSCLC require cytotoxic chemotherapy in the course of their illness. Combination chemotherapy using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with platinums(cisplatin or carboplatin) reached a plateau in their efficacy. Oxaliplatin, another platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects such as nausea and nephrotoxicity. In this phase II trial, we will observe efficacy and safety of docetaxel and oxaliplatin for patients with NSCLC. | http://clinicaltrials.gov/ct2/show/NCT01243775 - Retrieved October 2011 | Chonnam National University Hospital | Chong Kun Dang Pharmaceutical | Currently recruiting | Stage IV |
40 | 33 | http://clinicaltrials.gov/ct2/show/NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors | This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors. | http://clinicaltrials.gov/ct2/show/NCT01155258 - Retrieved October 2011 | USC/Norris Comprehensive Cancer Center | Wyeth is now a wholly owned subsidiary of Pfizer | Currently recruiting | Stage IV |
41 | 34 | http://clinicaltrials.gov/ct2/show/NCT00727441 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery | A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas | This randomized clinical trial is studying the side effects of vaccine therapy and to see how well it works when given with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT00727441 - Retrieved October 2011 | Sidney Kimmel Comprehensive Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
42 | 35 | http://clinicaltrials.gov/ct2/show/NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low- or Intermediate-Grade Neuroendocrine Cancer | Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | This phase I trial is studying the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer. | http://clinicaltrials.gov/ct2/show/NCT01204476 - Retrieved October 2011 | M.D. Anderson Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
43 | 36 | http://clinicaltrials.gov/ct2/show/NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery | A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma | This randomized phase III trial is studying gemcitabine hydrochloride and erlotinib hydrochloride to see how well they work compared with gemcitabine hydrochloride alone followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT01013649 - Retrieved October 2011 | Radiation Therapy Oncology Group | National Cancer Institute | Currently recruiting | Stage IV |
44 | 37 | http://clinicaltrials.gov/ct2/show/NCT00960284 | Gemcitabine Hydrochloride With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Pancreatic Cancer | Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil | This randomized phase II/III trial is studying gemcitabine hydrochloride to see how well it works when given alone or together with combination chemotherapy and radiation therapy in treating patients with stage IB, stage II, or stage III pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00960284 - Retrieved October 2011 | Istituto Scientifico H. San Raffaele | Currently recruiting | Stage IV | |
45 | 38 | http://clinicaltrials.gov/ct2/show/NCT01364805 | New Treatment Option for Pancreatic Cancer | Translation of in Vitro and in Vivo Ascorbate Research Into a New Treatment Option for Pancreatic Cancer: Phase I/IIa Clinical Trial | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01364805 - Retrieved October 2011 - Retrieved October 2011 | Jeanne Drisko, MD, CNS, FACN | Lotte and John Hecht Memorial Foundation; University of Kansas | Currently recruiting | Stage IV |
46 | 39 | http://clinicaltrials.gov/ct2/show/NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor | A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer | This phase II trial is studying the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. | http://clinicaltrials.gov/ct2/show/NCT01010126 - Retrieved October 2011 | Mayo Clinic | National Cancer Institute | Currently recruiting | Stage IV |
47 | 40 | http://clinicaltrials.gov/ct2/show/NCT01346410 | Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer | Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer | This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of unresectable pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01346410 - Retrieved October 2011 | St. John's Mercy Research Institute, St. Louis | Currently recruiting | Stage IV | |
48 | 41 | http://clinicaltrials.gov/ct2/show/NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma | This randomized phase II trial is studying how well giving dasatinib together with gemcitabine hydrochloride works compared to giving gemcitabine hydrochloride alone in treating patients with pancreatic cancer previously treated with surgery. | http://clinicaltrials.gov/ct2/show/NCT01234935 - Retrieved October 2011 | Translational Oncology Research International | National Cancer Institute | Currently recruiting | Stage IV |
49 | 42 | http://clinicaltrials.gov/ct2/show/NCT01182246 | AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer | Safety, Pharmacokinetics and Efficacy of AXP107-11 in Combination With Standard Gemcitabine (Gemzar®) Treatment in Patients With Locally Advanced or Metastatic, Unresectable, Adenocarcinoma of the Pancreas, Stage III-IV: A Prospective, Open Label, Multi-centre, Sequential Phase Ib/IIa Study | The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas. The safety, pharmacokinetics and efficacy of AXP107-11 in these patients will also be studied. | http://clinicaltrials.gov/ct2/show/NCT01182246 - Retrieved October 2011 | Axcentua Pharmaceuticals AB | Currently recruiting | Stage IV | |
50 | 43 | http://clinicaltrials.gov/ct2/show/NCT01025882 | Stereotactic Body Radiation Therapy With or Without Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | Phase I Study of Margin-Intense Combination Therapy for Patients With Potentially Resectable Pancreatic Adenocarcinoma | This phase I trial is studying the side effects of stereotactic body radiation therapy when given with or without gemcitabine hydrochloride in treating patients with pancreatic cancer that can be removed by surgery. | http://clinicaltrials.gov/ct2/show/NCT01025882 - Retrieved October 2011 | Simmons Cancer Center | Currently recruiting | Stage IV | |
51 | 44 | http://clinicaltrials.gov/ct2/show/NCT01413022 | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | This phase I trial studies the side effects and optimal dose of PF-04136309 when given with combination chemotherapy (FOLFIRINOX; 5-fluoroucil, leucovorin, irinotecan, oxaliplatin) in treating patients with locally advanced or borderline resectable pancreatic cancer. These patients are not candidates for surgical resection which is the most effective treatment for pancreatic cancer. Giving PF-04136309 together with FOLFIRINOX may shrink pancreatic tumors in some patients so that surgery becomes an option | http://clinicaltrials.gov/ct2/show/NCT01413022 - Retrieved October 2011 | Washington University School of Medicine | National Cancer Institute | Not yet recruiting | Stage IV |
52 | 45 | http://clinicaltrials.gov/ct2/show/NCT00882310 | A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer | A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00882310 - Retrieved October 2011 | Columbia University | Currently recruiting | Stage IV | |
53 | 46 | http://clinicaltrials.gov/ct2/show/NCT01298011 | Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer | A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer | The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01298011 - Retrieved October 2011 | Pancreatic Cancer Research Team | Celgene Corporation | Currently recruiting | Stage IV |
54 | 47 | http://clinicaltrials.gov/ct2/show/NCT01121848 | Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | A Randomized Phase III Study of Capecitabine or 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy | Primary Objective: To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) or Capecitabine will improve the Progression-Free Survival (PFS). Progression is based on RECIST (Response Evaluation Criteria In Solid Tumors) criteria or death; Secondary Objective: To evaluate other measures of tumor's responses and safety | http://clinicaltrials.gov/ct2/show/NCT01121848 - Retrieved October 2011 | Sanofi-Aventis | Currently recruiting | Stage IV | |
55 | 48 | http://clinicaltrials.gov/ct2/show/NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2) | Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with gemcitabine in patients with solid malignancy; Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of LY2157299 and gemcitabine with that of gemcitabine plus placebo. | http://clinicaltrials.gov/ct2/show/NCT01373164 - Retrieved October 2011 | Eli Lilly and Company | Currently recruiting | Stage IV | |
56 | 49 | http://clinicaltrials.gov/ct2/show/NCT01065870 | Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) | Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma | This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. The purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only venous involvement. Group II patients have arterial involvement and may also have venous involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01065870 - Retrieved October 2011 | Columbia University | Currently recruiting | Stage IV | |
57 | 50 | http://clinicaltrials.gov/ct2/show/NCT01019382 | A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer | Phase II Trial of the Effect of Gemcitabine With Intravenous Omega-3 Fish Oil Infusion in Patients With Unresectable Pancreatic Adenocarcinoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01019382 - Retrieved October 2011 | University Hospitals, Leicester | B. Braun Medical Inc. | Currently recruiting | Stage IV |
58 | 51 | http://clinicaltrials.gov/ct2/show/NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine Versus Gemcitabine Alone in Treatment-Naive Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819) | A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine Versus Gemcitabine Alone in Treatment-Naïve Patients With Locally Advanced Pancreatic Adenocarcinoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01413087 - Retrieved October 2011 | BioCancell Therapeutics Israel Ltd. | Currently recruiting | Stage IV | |
59 | 52 | http://clinicaltrials.gov/ct2/show/NCT01210911 | Metformin Combined With Chemotherapy for Pancreatic Cancer (GEM) | A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01210911 - Retrieved October 2011 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Currently recruiting | Stage IV | |
60 | 53 | http://clinicaltrials.gov/ct2/show/NCT00609336 | Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery | A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma | This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy, such as IMRT, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug (combination chemotherapy) together with intensity-modulated radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery | http://clinicaltrials.gov/ct2/show/NCT00609336 - Retrieved October 2011 | Fred Hutchinson Cancer Research Center | National Cancer Institute | Currently recruiting | Stage IV |
61 | 54 | http://clinicaltrials.gov/ct2/show/NCT01068327 | Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer | A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer | This phase I trial is studying the side effects and best dose of stereotactic radiation therapy and nelfinavir mesylate when given together with gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer | http://clinicaltrials.gov/ct2/show/NCT01068327 - Retrieved October 2011 | University of Nebraska | National Cancer Institute | Currently recruiting | Stage IV |
62 | 55 | http://clinicaltrials.gov/ct2/show/NCT00667082 | Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat (Zolinza; a HDAC inhibitor) in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma. Proteasome inhibitors block the breakdown of proteins by cells and HDAC inhibitors block modification of proteins regulating gene expression in cells. Both of these actions preferentially affect cancer cells, and the combination of the two has been seen to have a greater effect in laboratory studies | http://clinicaltrials.gov/ct2/show/NCT00667082 - Retrieved October 2011 | Nereus Pharmaceuticals, Inc. | Currently recruiting | Stage IV | |
63 | 56 | http://clinicaltrials.gov/ct2/show/NCT01198522 | Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | Phase I/II Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01198522 - Retrieved October 2011 | Philogen S.p.A. | Currently recruiting | Stage IV | |
64 | 57 | http://clinicaltrials.gov/ct2/show/NCT00689065 | Safety Study of CALAA-01 to Treat Solid Tumor Cancers | A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00689065 - Retrieved October 2011 | Calando Pharmaceuticals | Currently recruiting | Stage IV | |
65 | 58 | http://clinicaltrials.gov/ct2/show/NCT00614653 | Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer | The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00614653 - Retrieved October 2011 | M.D. Anderson Cancer Center | Genentech | Currently recruiting | Stage IV |
66 | 59 | http://clinicaltrials.gov/ct2/show/NCT01042028 | A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer | A Randomised Fase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer | This is an open multicenter randomized phase I/II study. The main purpose with this study is to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus given biweekly to patients with local advanced or metastatic pancreatic cancer AFTER progression from 1. line treatment with Gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT01042028 - Retrieved October 2011 | Odense University Hospital | Not yet recruiting | Stage IV | |
67 | 60 | http://clinicaltrials.gov/ct2/show/NCT01438476 | Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas | Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection | The goal of this clinical research study is to learn if there is a difference in patients' quality of recovery if they receive 1 of 2 standard kinds of pain control treatments after surgery on the liver and/or pancreas. Researchers want to learn which method helps people to recover more completely and more quickly after surgery. The 2 kinds of pain control are intravenous (IV) pain management and epidural pain management | http://clinicaltrials.gov/ct2/show/NCT01438476 - Retrieved October 2011 | M.D. Anderson Cancer Center | Not yet recruiting | Stage IV | |
68 | 61 | http://clinicaltrials.gov/ct2/show/NCT01420874 | Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib) | The purpose of this research study is for the participant to give their own T cells (a type of blood cell in the body that can fight infections and possibly cancer) to them after they have been removed, grown in a lab, and then coated with an experimental drug. This study will determine the highest dose of EGFR2Bi coated T cells that can be given without causing severe side effects. Initially a group of 3 participants will receive the same dose of study drug. If no serious side effects occur, the next group of participants will receive a slightly higher dose of study agent. The following groups of participants will receive higher doses of the study drug until a dose is reached where there are unacceptable side effects and maximum tolerated dose is found, or the planned highest dose level is reached with no side effects. | http://clinicaltrials.gov/ct2/show/NCT01420874 - Retrieved October 2011 | Barbara Ann Karmanos Cancer Institute | Currently recruiting | Stage IV | |
69 | 62 | http://clinicaltrials.gov/ct2/show/NCT01181245 | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | Objectives: Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib; Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib. | http://clinicaltrials.gov/ct2/show/NCT01181245 - Retrieved October 2011 | FibroGen | Currently recruiting | Stage IV | |
70 | 63 | http://clinicaltrials.gov/ct2/show/NCT01077427 | Hyperthermia European Adjuvant Trial (HEAT) | A Phase III, Randomized, Open Multicenter Trial of Adjuvant Gemcitabine Chemotherapy With the Addition of Regional Hyperthermia in First-line Treatment of Patients With R0/R1 Resected Pancreatic Carcinoma | The addition of regional hyperthermia to standard chemotherapy (gemcitabine) in an adjuvant setting may improve the outcome of patients with pancreatic cancer. The present trial is performed in order to confirm the hypothesis that the addition of regional hyperthermia (RHT) to gemcitabine standard therapy (G + RHT) for pancreatic cancer patients after R0/R1-tumor resection is superior to gemcitabine standard therapy alone (G). | http://clinicaltrials.gov/ct2/show/NCT01077427 - Retrieved October 2011 | Klinikum der Universitaet Muenchen, Grosshadern | European Society for Hyperthermic Oncology; Institute for Medical Informatics, Biometry and Epidemiology, Munich ClinAssess GmbH, Leverkusen, Germany | Currently recruiting | Stage IV |
71 | 64 | http://clinicaltrials.gov/ct2/show/NCT01362582 | Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer (PANUSCO) | Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy | A randomised multicentre clinical phase IIIb trial for patients suffering from pancreatic adenocarcinoma receiving defined second or higher line chemotherapy and additionally parenteral nutrition (study arm A) or best supportive nutritional care (study arm B). | http://clinicaltrials.gov/ct2/show/NCT01362582 - Retrieved October 2011 | National Center for Tumor Diseases, Heidelberg | University of Heidelberg, Institute of Medical Biometry and Informatics; University of Heidelberg, Dept. of General, Visceral and Transplantation Surgery | Currently recruiting | Stage IV |
72 | 65 | http://clinicaltrials.gov/ct2/show/NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | A Phase II Study Evaluating the Rate of R0 Resection (Microscopically Negative Margins) After Induction Therapy With 5- Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan (FOLFIRINOX) in Patients With Borderline Resectable or Locally Advanced Inoperable Pancreatic Cancer. | The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancreatic cancer. Based on the FOLFIRINOX regimen for advanced pancreatic cancer, a phase II study of this regimen in patients with locally advanced unresectable and borderline pancreatic cancer is planned to determine the rate of conversion to operability. | http://clinicaltrials.gov/ct2/show/NCT01359007 - Retrieved October 2011 | University of Oklahoma | Currently recruiting | Stage IV | |
73 | 66 | http://clinicaltrials.gov/ct2/show/NCT01391143 | Safety Study of MGA271 in Refractory Cancer | A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer | The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors. | http://clinicaltrials.gov/ct2/show/NCT01391143 - Retrieved October 2011 | MacroGenics | Currently recruiting | Stage IV | |
74 | 67 | http://clinicaltrials.gov/ct2/show/NCT00839332 | A Study for Patients With Pancreatic Cancer | A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer | The purpose of the Phase 1 portion of this study is to determine the safe dose of LY2603618 when given 24 hours after gemcitabine. This dose will then be used for the Phase 2 portion of the study. The Phase 2 portion of the study will evaluate whether LY2603618 when administered 24 hours after gemcitabine therapy is an effective treatment for patients with pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00839332 - Retrieved October 2011 | Eli Lilly and Company | Currently recruiting | Stage IV | |
75 | 68 | http://clinicaltrials.gov/ct2/show/NCT00763516 | Proton Therapy for Resectable Carcinoma of the Pancreas (PC02) | A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT00763516 - Retrieved October 2011 | University of Florida | Currently recruiting | Stage IV | |
76 | 69 | http://clinicaltrials.gov/ct2/show/NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer (BAGPAC) | A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01251640 - Retrieved October 2011 | Bayer | Currently recruiting | Stage IV | |
77 | 70 | http://clinicaltrials.gov/ct2/show/NCT01146054 | Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma | Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma | This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01146054 - Retrieved October 2011 | Stanford University | John Hopkins University | Currently recruiting | Stage IV |
78 | 71 | http://clinicaltrials.gov/ct2/show/NCT01383538 | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01383538 - Retrieved October 2011 | University of California, San Francisco | Infinity Pharmaceuticals | Currently recruiting | Stage IV |
79 | 72 | http://clinicaltrials.gov/ct2/show/NCT01300533 | A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer | The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01300533 - Retrieved October 2011 | BIND Biosciences | Currently recruiting | Stage IV | |
80 | 73 | http://clinicaltrials.gov/ct2/show/NCT01219192 | Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure | Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure | The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure. | http://clinicaltrials.gov/ct2/show/NCT01219192 - Retrieved October 2011 | Protgen Ltd | Currently recruiting | Stage IV | |
81 | 74 | http://clinicaltrials.gov/ct2/show/NCT00869258 | Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar | Phase II Study for Inoperable Non-Metastatic Pancreatic Cancer (Stage IVA) With Neoadjuvant Gemzar, Taxotere and Xeloda (GTX), and Radiation With Gemzar | The purpose of this study is to determine whether an experimental drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) when followed by radiation therapy plus low-dose Gemzar, is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00869258 - Retrieved October 2011 | Columbia University | Currently recruiting | Stage IV | |
82 | 75 | http://clinicaltrials.gov/ct2/show/NCT00690300 | Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer | The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy. | http://clinicaltrials.gov/ct2/show/NCT00690300 - Retrieved October 2011 | University of Ulm | Currently recruiting | Stage IV | |
83 | 76 | http://clinicaltrials.gov/ct2/show/NCT01231347 | GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas | AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. Gemcitabine is administered on days 1, 8 and 15 of a 28 day cycle, AMG 479 or placebo is administered on days 1 and 15 of the 28 day cycle, both are administered intravenously. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT01231347 - Retrieved October 2011 | Amgen | Takeda Global Research & Development Center, Inc. | Currently recruiting | Stage IV |
84 | 77 | http://clinicaltrials.gov/ct2/show/NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer (LAPC) | Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer | The purpose of this study determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone. | http://clinicaltrials.gov/ct2/show/NCT01395017 - Retrieved October 2011 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Currently recruiting | Stage IV | |
85 | 78 | http://clinicaltrials.gov/ct2/show/NCT00920023 | Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) | Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) | The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection. | http://clinicaltrials.gov/ct2/show/NCT00920023 - Retrieved October 2011 | Massachusetts General Hospital | Currently recruiting | Stage IV | |
86 | 79 | http://clinicaltrials.gov/ct2/show/NCT01189929 | A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer | A Phase 1b Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, OMP21M18, when given in combination with gemcitabine, a drug that is a standard treatment for advanced pancreatic cancer that has not been treated previously with chemotherapy. OMP 21M18 is a humanized monoclonal antibody (a protein made in the laboratory) and was developed to target cancer stem cells. The way the body handles OMP21M18 will also be investigated. Up to 32 participants, 21 years or older, will be enrolled at up to 6 centres in Australia and New Zealand. Following informed consent and screening, participants will receive intravenous infusions of OMP21M18 every other week and Gemcitabine administered weekly for the first 7 weeks. After 9 weeks, participants will undergo assessments to determine their disease status. Participants will continue to receive infusions of OMP21M18 every other week and gemcitabine once weekly for 3 consecutive weeks out of every 4 weeks until disease progression. | http://clinicaltrials.gov/ct2/show/NCT01189929 - Retrieved October 2011 | OncoMed Pharmaceuticals, Inc. | Novotech (Australia) Pty Ltd. | Currently recruiting | Stage IV |
87 | 80 | http://clinicaltrials.gov/ct2/show/NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | A Phase 2 Study of Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | This phase II study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01333124 - Retrieved October 2011 | National Cancer Center, Korea | Currently recruiting | Stage IV | |
88 | 81 | http://clinicaltrials.gov/ct2/show/NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity | Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective Study | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01371240 - Retrieved October 2011 | University Hospital Case Medical Center | Repligen Corporation | Currently recruiting | Stage IV |
89 | 82 | http://clinicaltrials.gov/ct2/show/NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | Refer to clinical trial website. | http://clinicaltrials.gov/ct2/show/NCT01206296 - Retrieved October 2011 | Washington Hospital Center | Currently recruiting | Stage IV | |
90 | 83 | http://clinicaltrials.gov/ct2/show/NCT01048320 | Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer (RPGOG1) | A Phase I Study of Gemcitabine Plus Oxaliplatin in Combination With Imatinib Mesylate (Glivec) in Patients With Gemcitabine-refractory Advanced Adenocarcinoma of the Pancreas | The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer that has progressed during or after treatment with first-line gemcitabine. | http://clinicaltrials.gov/ct2/show/NCT01048320 - Retrieved October 2011 | Royal Marsden NHS Foundation Trust | Currently recruiting | Stage IV | |
91 | 84 | http://clinicaltrials.gov/ct2/show/NCT01166490 | A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic Adenocarcinoma | A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic Adenocarcinoma | This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and to identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic adenocarcinoma. | http://clinicaltrials.gov/ct2/show/NCT01166490 - Retrieved October 2011 | Seattle Genetics, Inc. | Astellas Pharma Inc | Currently recruiting | Stage IV |
92 | 85 | http://clinicaltrials.gov/ct2/show/NCT00733850 | Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer | A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer | Gemcitabine is usually used to treat cancer of the pancreas. The purpose of this study is to determine if Kanglaite Injection (KLT) is safe in patients with cancer of the pancreas, and whether it improves the effectiveness of gemcitabine. Additionally, the effect, if any, of KLT on the signs and symptoms of cancer as well as the common side effects of chemotherapy will be evaluated. The research drug, KLT, is purified from a traditional Chinese medicine called coix seed. It is approved in China for use in combination with chemotherapy to treat patients with advanced lung cancer and liver cancer. It is also approved in China for use by itself to treat the symptoms of cancer in patients with advanced cancer of any kind. In the US, KLT is purely experimental and is not approved for any use. While a small number of cancer patients in the US have received KLT alone in a Phase I study, this is the first US protocol to evaluate whether or not KLT is useful in pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00733850 - Retrieved October 2011 | KangLaiTe USA | Currently recruiting | Stage IV | |
93 | 86 | http://clinicaltrials.gov/ct2/show/NCT01161186 | Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT01161186 - Retrieved October 2011 | University of California, San Francisco | Abraxis BioScience, LLC. | Currently recruiting | Stage IV |
94 | 87 | http://clinicaltrials.gov/ct2/show/NCT00726037 | A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer | This study is designed to determine the following: 1-The degree and duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration; 2-To determine the safety of anti-CD4/CD25 monoclonal antibody (Ontak) in patients with metastatic pancreatic cancer; 3-To follow patients treated with Ontak for a clinical response as determined by Ca 19-9 and CT scans | http://clinicaltrials.gov/ct2/show/NCT00726037 - Retrieved October 2011 | Loyola University | Riveria Country Club Organization; Eisai, Inc. | Currently recruiting | Stage IV |
95 | 88 | http://clinicaltrials.gov/ct2/show/NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas | The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe. The secondary goal is to determine if this new treatment regimen can effectively treat pancreatic cancer. This study will test the safety and efficacy of this combination in two parts, or phases. | http://clinicaltrials.gov/ct2/show/NCT01128296 - Retrieved October 2011 | University of Pittsburgh | National Institutes of Health (NIH) | Currently recruiting | Stage IV |
96 | 89 | http://clinicaltrials.gov/ct2/show/NCT01111591 | Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer | Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. | In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate. | http://clinicaltrials.gov/ct2/show/NCT01111591 - Retrieved October 2011 | Seoul National University Hospital | Seoul National University Bundang Hospital | Currently recruiting | Stage IV |
97 | 90 | http://clinicaltrials.gov/ct2/show/NCT01401387 | Pancreatic Enzyme Suppletion in Pancreatic Cancer (EPC) | Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy | This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine pancreatic insufficiency during their disease process. | http://clinicaltrials.gov/ct2/show/NCT01401387 - Retrieved October 2011 | Foundation for Liver Research | Not yet recruiting | Stage IV | |
98 | 91 | http://clinicaltrials.gov/ct2/show/NCT00968604 | C-VISA BikDD: Liposome in Advanced Pancreatic Cancer | A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of the BikDD Nanoparticle in Patients With Advanced Pancreatic Cancer | The goal of this clinical research study is to find the highest tolerable dose of BikDD nanoparticle that can be given to patients with advanced cancer of the pancreas. The safety of this drug will also be studied. | http://clinicaltrials.gov/ct2/show/NCT00968604 - Retrieved October 2011 | M.D. Anderson Cancer Center | National Cancer Institute | Currently recruiting | Stage IV |
99 | 92 | http://clinicaltrials.gov/ct2/show/NCT00966277 | Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients | Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment | The goal of this clinical research study is to learn if dalteparin can lower the risk of venous thromboembolism (VTE) occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy. Some patients will receive dalteparin and some will receive no study drug. The safety of dalteparin will also be studied. | http://clinicaltrials.gov/ct2/show/NCT00966277 - Retrieved October 2011 | M.D. Anderson Cancer Center | Eisai Inc. | Currently recruiting | Stage IV |
100 | 93 | http://clinicaltrials.gov/ct2/show/NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma | The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with gemcitabine is effective and safe in the treatment of patients with advanced pancreatic cancer. | http://clinicaltrials.gov/ct2/show/NCT00998322 - Retrieved October 2011 | Oncolytics Biotech | University of Texas | Currently recruiting | Stage IV |